Corcept Therapeutics Incorporated (CORT) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Get detailed Corcept Therapeutics Incorporated (CORT) stock forecast for 2025, monthly, along with long-term CORT price prediction from 2025 to 2050. Look at historical stock performance, analyst recommendations (Buy, Sell, or Hold), and the latest Corcept Therapeutics Incorporated headlines.
1 Month Prediction
$91.60 [-19.81%]
3 Month Prediction
$114.33 [0.09%]
6 Month Prediction
$143.46 [25.60%]
1 Year Prediction
$183.08 [60.28%]
3 Year Prediction
$260.98 [128.49%]
5 Year Prediction
$304.96 [166.99%]
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a biotechnology company that develops medications that modulate the effects of cortisol to treat severe metabolic, oncologic, and psychiatric disorders.
The company's lead product, relacorilant, is a selective cortisol modulator currently in advanced clinical trials. It is being evaluated for its efficacy in treating platinum-resistant ovarian cancer and hypercortisolism, which is characterized by excessive cortisol levels.
One of their other products is Korlym, which controls hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery.
The company was founded in 1998, and based in Menlo Park, California.
Corcept Therapeutics Incorporated (CORT) Historical Performance
IPO Date
Corcept Therapeutics Incorporated (NASDAQ:CORT) went public on 15 April, 2004.
Change
Since inception, CORT has increased by 872.91%. In the last 5 years, CORT has risen from $12.66 to $114.22, a massive 802.21% increase since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $114.22 and a low of $12.66.
52 Week Range
$20.84
$117.33
The current price $114.22 is near the 52-week high, which means that the stock is overbought.
CORT Stock Price History
Based on CORT stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the CORT stock has risen from $11.89 - $26.16 to $60.58 - $114.22, which is up 554.21%. Currently, the stock follows upward trend.
Here, we have calculated stock range of CORT, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $11.89 - $26.16 | $16.04 | 30.24 | 1 Year Change |
| 2021 | $18.0 - $28.26 | $22.01 | 78.72 | 2 Year Change |
| 2022 | $18.77 - $28.66 | $23.67 | 92.2 | 3 Year Change |
| 2023 | $20.83 - $32.73 | $25.43 | 106.49 | 4 Year Change |
| 2024 | $21.1 - $57.68 | $36.09 | 193.04 | 5 Year Change |
| 2025 | $60.58 - $114.22 | $80.57 | 554.21 | 6 Year Change |
CORT Price Performance
6-Month Performance
CORT stock jumped by 133.24% in the last six months.
1-Year Performance
The stock has trended upwards by 389.79% in the past year.
3-Year Performance
In the last 3 years, the stock has soared by 431.01%.
5-Year Performance
In the last 5 years, the stock has gone up by 802.21%.
According to Corcept Therapeutics Incorporated's historical data, below graph gives us the exact picture of how the CORT stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 4 years and a decline in 1 year.
2020
116.20% ↑
2021
24.31% ↓
2022
2.58% ↑
2023
59.92% ↑
2024
55.14% ↑
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Corcept Therapeutics Incorporated (CORT) Financials & Stock Analysis
Total Revenue
Quarterly Revenue: $181.89 M (Q4)
Revenue for Q4 ending 31st December, 2024 decreased 0.36% compared to Q3 ending 30th September, 2024.
Annual Revenue: $675.04 M (1Y)
Revenue for trailing 12 months decreased 0.00% year over year from 31st December, 2024.
If compared to the last 4 years, the revenue has gone up from $365.98 million to $675.04 million, a 84.45% change.
Market Capitalization
Corcept Therapeutics Incorporated has a market capitalization of $12.05B, which places CORT in the large-cap category.
Fundamental Analysis
EPS: $nan (Q4), $1.35 (1Y)
EPS decreased nan% since last quarter, and increased 32.35% since last year.
Net Income: $30.75 M (Q4), $141.21 M (1Y)
Net Income decreased 34.88% since last quarter, and increased 33.04% since last year.
Free Cash Flow: $59.18 M (Q4), $195.90 M (1Y)
Free Cash Flow decreased 18.03% since last quarter, and increased 54.37% since last year.
Net Profit Margin: 16.90% (Q4), 20.92% (1Y)
Net Profit Margin decreased 34.64% since last quarter, and increased 33.04% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for CORT stock. These indicators help you understand Corcept Therapeutics Incorporated's financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for CORT stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $59.40 |
| SMA50 | $62.71 |
| SMA200 | $48.23 |
| RSI | 90.16 |
| Beta | 0.61 |
SMA20 < Current Price
This signals CORT stock is in short-term bullish momentum.
SMA50 < Current Price
This signals CORT stock is in mid-term bullish momentum.
SMA200 < Current Price
This signals CORT stock is in long-term bullish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for CORT stock is Bullish. Out of all indicators, 6 indicates bullish signals, 3 signals bearish trends and 0 gives neutral trends. The CORT stock forecast was last updated on 01 April, 2025.
Corcept Therapeutics Incorporated (CORT) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $173.16 by the end of 2025, and can reach around $146.66 to $213.49 in 2026. And, the long-term forecast suggests that the stock may further jump to $208.85 - $213.93 in 2028, and $225.04 - $477.04 by 2031. So, the CORT stock shows a strong upward trend in the next several years.
Short-term CORT Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-04 | $91.60 | -19.8% |
| 2025-05 | $105.02 | -8.05% |
| 2025-06 | $114.33 | 0.1% |
| 2025-07 | $126.95 | 11.15% |
| 2025-08 | $129.07 | 13.0% |
| 2025-09 | $143.46 | 25.6% |
| 2025-10 | $154.43 | 35.2% |
| 2025-11 | $159.40 | 39.56% |
| 2025-12 | $173.16 | 51.6% |
In 2025, the CORT stock price is expected to fluctuate between $91.6 and $173.16. According to the monthly forecast, the stock could rise to $173.16 by December 2024. If compared to the CORT's current price, the stock could gain 51.6% by the end of this year.
Long-term CORT Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $146.66 | $209.94 | $213.49 | 86.91% |
| 2027 | $206.39 | $144.40 | $238.44 | 108.76% |
| 2028 | $208.85 | $224.71 | $213.93 | 87.3% |
| 2029 | $295.42 | $308.13 | $287.95 | 152.1% |
| 2030 | $322.64 | $298.65 | $437.91 | 283.39% |
| 2031 | $225.04 | $280.18 | $477.04 | 317.65% |
| 2032 | $352.80 | $352.64 | $335.10 | 193.38% |
| 2033 | $362.75 | $467.34 | $488.30 | 327.51% |
| 2034 | $416.19 | $260.45 | $216.00 | 89.11% |
| 2035 | $482.34 | $432.71 | $536.04 | 369.3% |
| 2036 | $232.20 | $415.01 | $403.98 | 253.69% |
| 2037 | $516.24 | $686.68 | $272.57 | 138.64% |
| 2038 | $464.70 | $449.73 | $552.22 | 383.47% |
| 2039 | $497.57 | $388.39 | $505.77 | 342.8% |
| 2040 | $546.77 | $591.46 | $510.34 | 346.8% |
| 2041 | $464.28 | $442.89 | $452.01 | 295.74% |
| 2042 | $851.86 | $587.26 | $304.03 | 166.18% |
| 2043 | $580.25 | $815.18 | $535.51 | 368.84% |
| 2044 | $674.95 | $502.74 | $467.09 | 308.94% |
| 2045 | $781.34 | $474.81 | $768.33 | 572.68% |
| 2046 | $690.60 | $611.48 | $787.34 | 589.32% |
| 2047 | $614.66 | $491.98 | $548.34 | 380.07% |
| 2048 | $729.53 | $1155.40 | $769.14 | 573.38% |
| 2049 | $739.59 | $996.94 | $825.83 | 623.02% |
| 2050 | $376.32 | $725.29 | $646.43 | 465.95% |
| 2051 | $601.90 | $428.29 | $633.52 | 454.65% |
Corcept Therapeutics Incorporated (CORT) Stock Price Prediction & Forecast 2025
At the start of 2025, the CORT stock was at $66.92. Today, it is trading at $114.22, which is 70.68% increase from price at the beginning of the year. By the end of this year, you can expect the stock to reach to $173.16 by December 2025 with a 51.60% change.
Corcept Therapeutics Incorporated (CORT) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant appreciation in the CORT stock. During this period, the CORT's price is forecasted to shift from $146.66 to $437.91, which is 198.59% gain.
In 2026, the stock would possibly open at $146.66, escalates to $209.94 by mid-year, and wraps up at $213.49, reflecting a 86.91% increase from today's price. Further moving to 2030, the stock can kick off the year at $322.64, soar to $298.65 by mid-year, and finish at $437.91, which is 283.39% change from current price.
Corcept Therapeutics Incorporated (CORT) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $225.04 to $510.34, which is up 317.65%
In 2031, we can expect CORT to fluctuate between $225.04 and $477.04, a shift indicating a 317.65% gain by year-end compared to current price. And Until 2040, CORT can likely vary from $510.34 to $546.77. By the end of 2040, the stock could record a 346.81% rise from today's stock price.
Corcept Therapeutics Incorporated (CORT) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the CORT stock can see an an upturn from $464.28 to $646.43 in this period. In 2041, the stock can experience a low of $442.89 by mid-year, closing the year at $452.01. This results in a 287.76% increase from today.
Moving towards the end of 2050, CORT is projected to open the year at $376.32. The stock may peak to $725.29 during mid-year and finish the year at $646.43. Compared to the stock's current price, this translates to an overall gain of 465.95% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
CORT Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| GLTO | Galecto, Inc. | - | $6.65 | 51.83% ▲ | $32.48 ▲ |
| RNAZ | TransCode Therapeutics, Inc. | - | $1.38 | -30.31% ▼ | -27.53 ▼ |
| CRVO | CervoMed Inc. | - | $6.91 | 208.48% ▲ | $257.27 ▲ |
| SYRS | Syros Pharmaceuticals, Inc. | - | $0.14 | -4.90% ▼ | $3861.03 ▲ |
| ARVN | Arvinas, Inc. | - | $8.30 | -53.11% ▼ | $409.53 ▲ |
Last updated Apr 01 at 9:31 AM
CORT : Buy, Sell Or Hold?
Analyst Ratings
Based on 4 analysts, 2 rated as a strong buy, 2 recommended a buy, 0 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.Three months ago, out of 4 analysts, 2 analysts gave a strong buy rating, 2 a buy rating, 0 a hold rating, 0 advised selling, and 0 suggested a strong sell.So, according to analyst ratings, the recommendation for CORT stock is Buy.
Expert Analysis
According to CORT short-term and long-term forecast, Corcept Therapeutics Incorporated shares are projected to go up by 465.95%, and reach a value of $646.43 per share by 2050.
As per technical analysis, indicators show a Bullish sentiment, while Fear & Greed Index stands at 71.42857142857143, which signals Greed. Also, CORT has recorded 8/30 green days, which reflects a 38.095238095238095% positivity rate with a price volatility of 0.20%.
Plus, Price-to-Earnings (P/E) ratio of 92.861786 suggests that CORT stock is overvalued. So, Based on CORT prediction and analysis, it may be the best time to hold CORT stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "CORT” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.